ArticleCureus2025
Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimBruton's tyrosine kinase inhibitors (BTKi) are important targeted agents for hematological malignancies. Second-generation BTKi are considered to have fewer off-target enzyme effects than first-generation agents; however, real-world comparative data on adverse events (AEs) remain limited. AEs of special interest with BTKi include bone marrow suppression, infection, hemorrhage, and cardiac-related events. This study aimed to investigate the frequency and severity of AEs of special interest associated with the three BTKi, namely, ibrutinib (IBR), tirabrutinib (TIR), and acalabrutinib (ACB), in real-world clinical practice.
methodsWe retrospectively investigated cytopenia and non-hematologic toxicities, including infections, bleeding, and cardiovascular AEs, for up to one year in patients who received BTKi at Fujita Health University Hospital and an affiliated hospital between March 2016 and March 2025 (IBR, n = 24; TIR, n = 24; ACB, n = 5). Data were collected from electronic medical records and graded according to the Common Terminology Criteria for Adverse Events, version 5.0.
resultsIn the IBR group, the median age was 76 years (range, 76-81 years). Cytopenia, infections, bleeding, and cardiovascular AEs occurred in 21 (87.5%), nine (37.5%), eight (33.3%), and four (16.6%) patients, respectively. In the TIR group, the median age was 70 years (range, 64-76 years). Cytopenia, infections, and bleeding occurred in 17 (70.8%), seven (29.1%), and six (25.0%) patients, respectively. In the ACB group, the median age was 68 years (range, 52-75 years), and cytopenia was observed in four (80.0%) patients.
conclusionAll BTKi agents were associated with bone marrow suppression, infection, and bleeding, whereas cardiac-related AEs occurred only with IBR. Several Grade 3 or higher events were identified, underscoring the need for careful monitoring of patients receiving BTKi in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.